Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Comparative analysis of total salivary lipopolysaccharide chemical and biological properties with periodontal status.

Mcilwaine C, Strachan A, Harrington Z, Jerreat M, Belfield LA, Sandor V, Foey A, Zaric S.

Arch Oral Biol. 2020 Feb;110:104633. doi: 10.1016/j.archoralbio.2019.104633. Epub 2019 Dec 13.

PMID:
31855745
2.

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.

Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J.

N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30.

PMID:
31566309
3.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
4.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
5.

Fast determination of lactic, succinic, malic, tartaric, shikimic, and citric acids in red Vranec wines by CZE-ESI-QTOF-MS.

Ivanova-Petropulos V, Naceva Z, Sándor V, Makszin L, Deutsch-Nagy L, Berkics B, Stafilov T, Kilár F.

Electrophoresis. 2018 Jul;39(13):1597-1605. doi: 10.1002/elps.201700492.

PMID:
29635703
6.

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.

PMID:
29573941
7.
8.

Advanced online mass spectrometry detection of proteins separated by capillary isoelectric focusing after sequential injection.

Páger C, Biherczová N, Ligetvári R, Berkics BV, Pongrácz T, Sándor V, Bufa A, Poór V, Vojs Staňová A, Kilár F.

J Sep Sci. 2017 Dec;40(24):4825-4834. doi: 10.1002/jssc.201700695. Epub 2017 Nov 17.

PMID:
29064636
9.

Mass Spectrometry for Profiling LOS and Lipid A Structures from Whole-Cell Lysates: Directly from a Few Bacterial Colonies or from Liquid Broth Cultures.

Kocsis B, Kilár A, Péter S, Dörnyei Á, Sándor V, Kilár F.

Methods Mol Biol. 2017;1600:187-198. doi: 10.1007/978-1-4939-6958-6_17.

PMID:
28478568
10.
11.

Availability and quality of illegitimate somatropin products obtained from the Internet.

Vida RG, Fittler A, Mikulka I, Ábrahám E, Sándor V, Kilár F, Botz L.

Int J Clin Pharm. 2017 Feb;39(1):78-87. doi: 10.1007/s11096-016-0398-y. Epub 2016 Nov 25.

PMID:
27888454
12.

Characterization of complex, heterogeneous lipid A samples using HPLC-MS/MS technique I. Overall analysis with respect to acylation, phosphorylation and isobaric distribution.

Sándor V, Dörnyei Á, Makszin L, Kilár F, Péterfi Z, Kocsis B, Kilár A.

J Mass Spectrom. 2016 Nov;51(11):1043-1063. doi: 10.1002/jms.3839.

PMID:
27506631
13.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS.

J Clin Oncol. 2015 Dec 1;33(34):4039-47. doi: 10.1200/JCO.2015.61.4578. Epub 2015 Sep 8.

14.

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators.

Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11.

15.

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J.

Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):214-221.e1. doi: 10.1016/j.clml.2014.12.008. Epub 2014 Dec 27.

16.

Structural background for serological cross-reactivity between bacteria of different enterobacterial serotypes.

Makszin L, Péterfi Z, Blaskó Á, Sándor V, Kilár A, Dörnyei Á, Ősz E, Kilár F, Kocsis B.

Electrophoresis. 2015 Jun;36(11-12):1336-43. doi: 10.1002/elps.201400445. Epub 2015 Apr 17.

PMID:
25630395
17.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H; COMFORT-I investigators.

Haematologica. 2015 Apr;100(4):479-88. doi: 10.3324/haematol.2014.115840. Epub 2015 Jan 23.

18.

Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma.

Horváth K, Boros M, Bagoly T, Sándor V, Kilár F, Kemény A, Helyes Z, Szolcsányi J, Pintér E.

Neuropeptides. 2014 Dec;48(6):371-8. doi: 10.1016/j.npep.2014.10.001. Epub 2014 Oct 16.

PMID:
25455106
19.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Onco Targets Ther. 2013 Dec 17;7:13-21. doi: 10.2147/OTT.S53348. eCollection 2013.

20.

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.

Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2013 Oct 29;6(1):81. doi: 10.1186/1756-8722-6-81.

21.

Phytochemical evaluation of Lythrum salicaria extracts and their effects on guinea-pig ileum.

Bencsik T, Barthó L, Sándor V, Papp N, Benkó R, Felinger A, Kilár F, Horváth G.

Nat Prod Commun. 2013 Sep;8(9):1247-50.

PMID:
24273858
22.

A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM.

Cancer. 2014 Feb 15;120(4):513-20.

23.

Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.

Haematologica. 2013 Dec;98(12):1865-71. doi: 10.3324/haematol.2013.092155. Epub 2013 Sep 13.

24.

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C.

Haematologica. 2014 Feb;99(2):292-8. doi: 10.3324/haematol.2013.087650. Epub 2013 Aug 2.

25.

Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study.

Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S.

Leuk Res. 2013 Aug;37(8):911-6. doi: 10.1016/j.leukres.2013.04.017. Epub 2013 May 17.

PMID:
23684482
27.

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM.

Br J Haematol. 2013 May;161(4):508-16. doi: 10.1111/bjh.12274. Epub 2013 Mar 11.

28.

Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial.

Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.

J Clin Oncol. 2013 Apr 1;31(10):1285-92. doi: 10.1200/JCO.2012.44.4489. Epub 2013 Feb 19.

29.

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM.

N Engl J Med. 2012 Mar 1;366(9):799-807. doi: 10.1056/NEJMoa1110557.

30.

Preparation and investigation of bioactive transferrin-iron complexes formed with different synergistic anions.

Gálicza J, Vargová A, Sándor V, Orbán CK, András CD, Abrahám B, Lányi S, Kilár F.

Protein J. 2012 Jan;31(1):27-34. doi: 10.1007/s10930-011-9370-9.

PMID:
22101801
31.

A comparative study of some Veronica species.

Crişan G, Tămaş M, Miclăuş V, Krausz T, Sandor V.

Rev Med Chir Soc Med Nat Iasi. 2007 Jan-Mar;111(1):280-4.

PMID:
17595882
32.

Protective effects of amphetamine on gastric ulcerations induced by indomethacin in rats.

Sandor V, Cuparencu B, Dumitrascu DL, Birt MA, Krausz TL.

World J Gastroenterol. 2006 Nov 28;12(44):7168-71.

33.

Future perspectives for the development of P-glycoprotein modulators.

Sandor V, Fojo T, Bates SE.

Drug Resist Updat. 1998;1(3):190-200.

PMID:
17092805
34.

[The distribution and polymorphism of beta-2-adrenoreceptors in the bronchi].

Tiotiu A, Todea D, Tiotiu D, Sandor V.

Pneumologia. 2005 Oct-Dec;54(4):177-80. Review. Romanian.

PMID:
17069220
35.

Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues.

Scrivens PJ, Alaoui-Jamali MA, Giannini G, Wang T, Loignon M, Batist G, Sandor VA.

Mol Cancer Ther. 2003 Oct;2(10):1053-9.

36.

SarCNU, a nitrosourea analog on a day 1, 5, and 9 oral schedule: a phase I and pharmacokinetic study in patients with advanced solid tumors.

Panasci L, Stinson SF, Melnychuk D, Sandor V, Miller WH Jr, Batist G, Patenaude F, Bangash N, Panarello L, Alaoui-Jamali M, Sausville E.

J Clin Oncol. 2003 Jan 15;21(2):232-40.

PMID:
12525514
37.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

38.

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.

Piekarz RL, Robey R, Sandor V, Bakke S, Wilson WH, Dahmoush L, Kingma DM, Turner ML, Altemus R, Bates SE.

Blood. 2001 Nov 1;98(9):2865-8.

PMID:
11675364
39.

Bleomycin-induced lung toxicity and pentoxifylline.

Goffin J, Kreisman H, Sandor V.

J Clin Oncol. 2001 Jan 15;19(2):597-8. No abstract available.

PMID:
11208860
40.

Life-threatening tinnitus.

Javaheri S, Cohen V, Libman I, Sandor V.

Lancet. 2000 Jul 22;356(9226):308. No abstract available.

PMID:
11071187
41.

FR901228 causes mitotic arrest but does not alter microtubule polymerization.

Sandor V, Robbins AR, Robey R, Myers T, Sausville E, Bates SE, Sackett DL.

Anticancer Drugs. 2000 Jul;11(6):445-54.

PMID:
11001385
42.

P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.

Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE.

Br J Cancer. 2000 Sep;83(6):817-25.

43.

Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival.

Sandor V, Reed E, Sarosy G, Middleton LP, Davis P, Kohn E.

Ann Oncol. 1999 May;10(5):585-8.

PMID:
10416009
44.

Clodronate in metastatic breast cancer.

Panasci LC, Sandor V, Melnychuk D.

N Engl J Med. 1998 Dec 24;339(26):1940-1; author reply 1941. No abstract available.

PMID:
9874608
45.

Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles.

Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S, Fojo T.

Mol Pharmacol. 1998 Nov;54(5):802-14.

PMID:
9804615
46.

Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.

Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R.

J Clin Oncol. 1998 Sep;16(9):3000-6.

PMID:
9738568
47.

The role of MDR-1 in refractory lymphoma.

Sandor V, Wilson W, Fojo T, Bates SE.

Leuk Lymphoma. 1997 Dec;28(1-2):23-31. Review.

PMID:
9498700
48.

Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer.

Sandor V.

Lancet. 1997 Nov 1;350(9087):1325-6. No abstract available.

PMID:
9357429
49.

Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.

Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT, Bates SE.

Blood. 1997 May 15;89(10):3795-800.

PMID:
9160686
50.

Exacerbation of pseudogout by granulocyte colony-stimulating factor.

Sandor V, Hassan R, Kohn E.

Ann Intern Med. 1996 Nov 1;125(9):781. No abstract available.

PMID:
8929025

Supplemental Content

Loading ...
Support Center